logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Neuroblastoma

    FiltersReset Filters
    12 results

    • adreview

      (Iobenguane I-123)
      Medi-Physics Inc.
      Usage: AdreView is indicated for detecting primary or metastatic pheochromocytoma and neuroblastoma, and for assessing sympathetic innervation in patients with congestive heart failure (NYHA class II or III, LVEF ≤ 35%). It aids in identifying lower mortality risks but is not for therapy selection or monitoring.

    • cyclophosphamide

      (Cyclophosphamide for Injection)
      Slate Run Pharmaceuticals, LLC
      Usage: Cyclophosphamide for Injection is indicated for treating various malignancies, including malignant lymphomas, multiple myeloma, leukemias, and solid tumors like breast cancer and ovarian adenocarcinoma. It is also used for pediatric patients with biopsy-proven minimal change nephrotic syndrome unresponsive to corticosteroid therapy.

    • cyclophosphamide

      (cyclophosphamide injection, solution)
      Baxter Healthcare Corporation
      Usage: Cyclophosphamide Injection is indicated for treating malignant lymphomas, multiple myeloma, various leukemias, advanced mycosis fungoides, disseminated neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is often used alone or in combination with other antineoplastic agents.

    • cyclophosphamide

      (cyclophosphamide)
      Dr. Reddy's Laboratories Inc.
      Usage: Cyclophosphamide is indicated for treating malignant diseases in adults and pediatric patients, including various lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, and breast carcinoma. It is often used in combination with other antineoplastic agents.

    • cyclophosphamide

      (cyclophosphamide)
      Civica, Inc.
      Usage: Cyclophosphamide for Injection is indicated for treating various malignant diseases in adults and children, including malignant lymphomas, multiple myeloma, leukemias, and neuroblastoma. It is also used for pediatric patients with minimal change nephrotic syndrome who do not respond to or cannot tolerate corticosteroids.

    • cyclophosphamide

      (cyclophosphamide)
      NorthStar RxLLC
      Usage: Cyclophosphamide is indicated for treating various malignant diseases, including certain lymphomas, multiple myeloma, leukemias, advanced mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also used for pediatric patients with minimal change nephrotic syndrome unresponsive to corticosteroids.

    • cyclophosphamide

      (cyclophosphamide)
      Bamboo US BidCo LLC
      Usage: Cyclophosphamide is indicated for treating various malignant diseases, including advanced lymphomas, multiple myeloma, leukemias, and certain solid tumors. It is also used for pediatric patients with biopsy-proven minimal change nephrotic syndrome who have not responded to corticosteroid therapy. Safety in adults for nephrotic syndrome is unestablished.

    • doxorubicin hydrochloride

      (DOXORUBICIN HYDROCHLORIDE)
      Fresenius Kabi USA, LLC
      Usage: Doxorubicin Hydrochloride Injection is indicated for treating various cancers, including leukemias, Wilms' tumor, neuroblastoma, sarcomas, and several carcinomas. It is also used as adjuvant therapy for women with axillary lymph node involvement post-primary breast cancer resection.

    • frindovyx

      (Cyclophosphamide)
      Avyxa Pharma, LLC
      Usage: FRINDOVYX is indicated for treating malignant lymphomas, multiple myeloma, various leukemias, advanced mycosis fungoides, disseminated neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, and breast carcinoma in adult and pediatric patients. It is often used in combination with other antineoplastic agents.

    • unituxin

      (DINUTUXIMAB)
      United Therapeutics Corporation
      Usage: Unituxin (dinutuximab) is indicated for pediatric patients with high-risk neuroblastoma who show at least a partial response to prior multiagent therapy. It is used in combination with GM-CSF, IL-2, and 13-cis-retinoic acid for treatment.